LiMM Therapeutics is a biopharmaceutical company that harnesses the molecular cross-talk between neuronal and innate lymphoid cells.
LiMM Therapeutics has raised $2.9M in total funding. The most recent round was Grant. The last funding was announced in October 2021.
LiMM Therapeutics's investors include Seventure Partners, European Innovation Council, Portugal Ventures, PME Investimentos, 200M.
LiMM Therapeutics is headquartered in Paris, France.
LiMM Therapeutics is a biopharmaceutical company that harnesses the molecular cross-talk between neuronal and innate lymphoid cells.
LiMM Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"LiMM Therapeutics — Funding & Investors." VCBacked, October 6, 2021, https://www.vcbacked.co/company/limm-therapeutics. Accessed July 20, 2026.
VCBacked. (2021). LiMM Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/limm-therapeutics
{{cite web |title=LiMM Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/limm-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated